{
  "trial_id": "NCT03090035",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "diagnosis of chronic hepatitis C genotype 2 or 3",
      "label": "met",
      "evidence": "previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies"
    },
    {
      "criterion": "chronic inflammation compatible with a chronic viral hepatitis",
      "label": "met",
      "evidence": "recent biopsy was negative for hepatocellular carcinoma"
    }
  ],
  "exclusion": [
    {
      "criterion": "hepatitis genotype I and IV",
      "label": "not_met",
      "evidence": "no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease"
    }
  ],
  "notes": "Patient is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months with direct antiviral drugs added to his treatment 6 months ago.",
  "_meta": {
    "topic_id": "27",
    "trial_id": "NCT03090035",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}